A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

• ClinicalTrials.gov Identifier: NCT03048344
• Recruitment Status: Completed
• First Posted: February 9, 2017
• Last Update Posted: March 25, 2019
• Sponsor: Orsenix LLC
• Information provided by (Responsible Party): Orsenix LLC

Study Description

Brief Summary:

Part 1 will be conducted as an open-label, non-randomized, non-placebo-controlled dose escalation study using pre-specified doses. Subjects with the following advanced hematological disorders and no available therapies, and who satisfy all inclusion/exclusion criteria will be enrolled. The purpose is to identify the recommended dose of oral ORH-2014 in subjects with advanced hematological disorders.

Part 2 will be an expansion phase conducted as a single-arm, open-label study to further evaluate the safety and tolerability of ORH-2014 at the maximum tolerated dose (MTD) or recommended dose determined from Part 1 in the fasted state. Subjects with the same disease types as in Part 1 will be enrolled. All subjects will receive oral ORH-2014, in the fasted state, at the recommended dose for an initial period of up to 12 weeks. The purpose is to evaluate the safety and tolerability of oral ORH-2014 in a population of subjects with advanced hematological disorders when administered at the recommended dose.

Condition or disease	Intervention/treatment	Phase
Advanced Hematological Disorders	Drug: ORH-2014	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 12 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Part 1 of the study is parallel. Part 2 will be an expansion phase.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
• Actual Study Start Date: December 2, 2016
• Actual Primary Completion Date: February 28, 2019
• Actual Study Completion Date: February 28, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part 1; Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.	Drug: ORH-2014; ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
Experimental: Part 2; Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.	Drug: ORH-2014; ORH-2014 capsule at recommended dose orally.

Outcome Measures

Primary Outcome Measures :

1. To identify the recommended dose [ Time Frame: From baseline to Week 4 ]
   The recommended dose is determined by the number of patients who experience a dose limiting toxicity (DLT).
2. Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability of ORH-2014 when administered at the MTD or recommended dose [ Time Frame: Up to Week 28 ]

   To evaluate safety and tolerability the aggregate review will include but is not limited to:

   • NCI-CTCAE Grade 3 and 4 AEs, serious adverse events (SAEs), deaths;
   • Laboratory results;
   • Vital signs;
   • ECGs;
   • Individual subject profiles including, but not limited to: medical history, AEs, concomitant medications, laboratory results, and vital signs;
   • Subject disposition and screen failure rates.

Secondary Outcome Measures :

1. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by maximum observed concentration (Cmax) [ Time Frame: Baseline up to Week 24 ]
2. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by time to maximum concentration (Tmax) [ Time Frame: Baseline up to Week 24 ]
3. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent terminal elimination half-life (t1/2) [ Time Frame: Baseline up to Week 24 ]
4. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by area under the concentration-time curve from 0 to 24 hours (AUC0-24) [ Time Frame: Baseline up to Week 24 ]
5. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by area under the concentration-time curve extrapolated to infinity (AUC0-infinity) [ Time Frame: Baseline up to Week 24 ]
6. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent terminal elimination rate constant (λZ) [ Time Frame: Baseline up to Week 24 ]
7. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total clearance (CL/F) [ Time Frame: Baseline up to Week 24 ]
8. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total clearance normalized by body weight (CL/F/kg) [ Time Frame: Baseline up to Week 24 ]
9. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total volume of distribution (Vz/F) [ Time Frame: Baseline up to Week 24 ]
10. To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by accumulation ratio (AR) [ Time Frame: Baseline up to Week 24 ]
11. To evaluate the effect of ORH-2014 on QT-interval corrected for heart rate using Fridericia's formula (QTcF) [ Time Frame: Baseline up to Week 28 ]
12. Safety Assessment during the expansion phase of the study on the effect of oral ORH-2014 on safety parameters [ Time Frame: Baseline up to Week 28 ]

    During the expansion phase of the study, an aggregate clinical data review (ACDR) will be conducted. This review will collect data from electronic data capture, the ECG central review vendor (ERT), and other sources to include but is not limited to:

    • NCI-CTCAE Grade 3 and 4 AEs, SAEs, deaths;
    • Laboratory results;
    • Vital signs;
    • ECG's;
    • Individual subject profiles including, but not limited to: medical history, AEs, concomitant medications, laboratory results, and vital signs;
    • Subject disposition and screen failure rates.
13. The number of participants with a complete response (CR) or partial response (PR) according to International Working Group (IWG) response criteria [ Time Frame: Up to Week 24 ]
    Bone marrow aspirates and/or biopsies will be obtained at the designated timepoints for evaluation of efficacy. Response criteria will be according to the International Working Group. Responders are participants who obtain complete remission (CR) or partial remission (PR), with or without cytogenetic response, and marrow complete remission.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Female and male subjects ≥18 years of age with one of the following:

  • Relapsed or refractory acute myelocytic leukemia (AML) with nucleophosmin-1 (NPM1) mutations and no available therapies.
  • Relapsed or refractory acute promyelocytic leukemia (APL), with no available therapies. Note: Prior exposure to arsenic trioxide is allowed; however, subjects who have failed arsenic trioxide within the last 12 months are not allowed.
  • Relapsed or refractory myelodysplastic syndrome (MDS), International Prognostic Scoring System intermediate or high-risk, with no available therapies
  • Relapsed or refractory chronic myelomonocytic leukemia (CMML), and other MDS/myeloproliferative neoplasm (MPN) overlap syndromes, with no available therapies
  • Relapsed or refractory mantle cell lymphoma (MCL) with no adequate therapies.
• Negative pregnancy test at the Screening visit for women of childbearing potential and willingness to use adequate birth control
• Not willing to undergo, not a candidate for, or not having a donor for immediate (within 3 months from the Screening date) bone marrow transplantation.

Exclusion Criteria:

• Eastern Cooperative Oncology Group performance status of ≥3;
• Absolute myeloblast count ≥20,000/mm^3;
• Administration of any antineoplastic therapy within 5 half-lives of the antineoplastic therapy before the first dose of ORH-2014, with the exception of hydroxyurea that should be discontinued 1 day prior to the first dose of ORH-2014
• Presence of any remaining toxicities due to previous chemotherapy
• Participation in other clinical trials within at least 2 weeks of the first ORH-2014 dose;
• Clinical evidence of active central nervous system leukemia;
• Active and uncontrolled infection
• Major surgery within 2 weeks prior to trial entry;
• Liver function tests above the following limits at Screening: total bilirubin >1.5 x upper limit of normal (ULN) unless related to Gilbert's syndrome or hemolysis; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x ULN; for subjects with liver involvement, AST and/or ALT >5 x ULN;
• Serum creatinine >1.5 x ULN and/or creatinine clearance or estimated glomerular filtration rate <30 mL/min
• Impaired cardiac function
• Myocardial infarction of unstable angina within 6 months prior to the planned start date of study drug.

Contacts and Locations

Locations

United States, New York

Memorial Sloan-Kettering Cancer Center

New York, New York, United States, 10065

Weill Cornell Medical College

New York, New York, United States, 10065

United States, Tennessee

Vanderbilt University

Nashville, Tennessee, United States, 37240

United States, Texas

MD Anderson

Houston, Texas, United States, 77030

Sponsors and Collaborators

Orsenix LLC

Investigators

• Principal Investigator: Farhad Ravandi-Kashani, MD; MD Anderson

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, Garcia-Manero G, Borthakur G, Naqvi K, Meyer M, Pudipeddi M, Nidarmarthy S, Vaddi K, Kantarjian H. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica. 2020 Jun;105(6):1567-1574. doi: 10.3324/haematol.2019.229583. Epub 2019 Sep 26.

• Responsible Party: Orsenix LLC
• ClinicalTrials.gov Identifier: NCT03048344
• Other Study ID Numbers: ORH2014-001
• First Posted: February 9, 2017
• Last Update Posted: March 25, 2019
• Last Verified: March 2019

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Orsenix LLC:

acute promyelocytic leukemia; APL; arsenic trioxide

Additional relevant MeSH terms:

Hematologic Diseases